. 2014 Dec 2:5:5694.

doi: 10.1038/ncomms6694.

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

Georgina V Long¹, Carina Fung², Alexander M Menzies³, Gulietta M Pupo⁴, Matteo S Carlino⁵, Jessica Hyman⁶, Hamideh Shahheydari², Varsha Tembe⁴, John F Thompson⁷, Robyn P Saw⁷, Julie Howle⁸, Nicholas K Hayward⁹, Peter Johansson⁹, Richard A Scolyer¹⁰, Richard F Kefford¹¹, Helen Rizos²

Affiliations

¹ 1] Melanoma Institute Australia, Sydney, New South Wales 2060, Australia [2] Discipline of Medicine, Sydney Medical School, The University of Sydney, Sydney, New South Wales 2006, Australia [3] Mater Hospital, North Sydney, New South Wales 2060, Australia.
² 1] Precision Cancer Therapy Laboratory, Australian School of Advanced Medicine, Macquarie University, Sydney, New South Wales 2109, Australia [2] Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia.
³ 1] Melanoma Institute Australia, Sydney, New South Wales 2060, Australia [2] Discipline of Medicine, Sydney Medical School, The University of Sydney, Sydney, New South Wales 2006, Australia [3] Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales 2145, Australia.
⁴ Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia.
⁵ 1] Melanoma Institute Australia, Sydney, New South Wales 2060, Australia [2] Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia [3] Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales 2145, Australia.
⁶ 1] Melanoma Institute Australia, Sydney, New South Wales 2060, Australia [2] Departments of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales 2006, Australia.
⁷ 1] Melanoma Institute Australia, Sydney, New South Wales 2060, Australia [2] Discipline of Surgery, Sydney Medical School, The University of Sydney, Sydney, New South Wales 2006, Australia [3] Departments of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales 2006, Australia.
⁸ 1] Melanoma Institute Australia, Sydney, New South Wales 2060, Australia [2] Discipline of Surgery, Sydney Medical School, The University of Sydney, Sydney, New South Wales 2006, Australia [3] Department of Surgical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales 2145, Australia.
⁹ Oncogenomics Laboratory, QIMR Berghofer Medical Research Institute, Herston, Brisbane, Queensland 4006, Australia.
¹⁰ 1] Melanoma Institute Australia, Sydney, New South Wales 2060, Australia [2] Departments of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales 2006, Australia [3] Discipline of Pathology, Sydney Medical School, The University of Sydney, Sydney, New South Wales 2006, Australia.
¹¹ 1] Melanoma Institute Australia, Sydney, New South Wales 2060, Australia [2] Discipline of Medicine, Sydney Medical School, The University of Sydney, Sydney, New South Wales 2006, Australia [3] Precision Cancer Therapy Laboratory, Australian School of Advanced Medicine, Macquarie University, Sydney, New South Wales 2109, Australia [4] Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia.

PMID: 25452114
DOI: 10.1038/ncomms6694

Free article

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

Georgina V Long et al. Nat Commun. 2014.

Free article

. 2014 Dec 2:5:5694.

doi: 10.1038/ncomms6694.

Authors

Affiliations

¹ 1] Melanoma Institute Australia, Sydney, New South Wales 2060, Australia [2] Discipline of Medicine, Sydney Medical School, The University of Sydney, Sydney, New South Wales 2006, Australia [3] Mater Hospital, North Sydney, New South Wales 2060, Australia.
² 1] Precision Cancer Therapy Laboratory, Australian School of Advanced Medicine, Macquarie University, Sydney, New South Wales 2109, Australia [2] Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia.
³ 1] Melanoma Institute Australia, Sydney, New South Wales 2060, Australia [2] Discipline of Medicine, Sydney Medical School, The University of Sydney, Sydney, New South Wales 2006, Australia [3] Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales 2145, Australia.
⁴ Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia.
⁵ 1] Melanoma Institute Australia, Sydney, New South Wales 2060, Australia [2] Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia [3] Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales 2145, Australia.
⁶ 1] Melanoma Institute Australia, Sydney, New South Wales 2060, Australia [2] Departments of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales 2006, Australia.
⁷ 1] Melanoma Institute Australia, Sydney, New South Wales 2060, Australia [2] Discipline of Surgery, Sydney Medical School, The University of Sydney, Sydney, New South Wales 2006, Australia [3] Departments of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales 2006, Australia.
⁸ 1] Melanoma Institute Australia, Sydney, New South Wales 2060, Australia [2] Discipline of Surgery, Sydney Medical School, The University of Sydney, Sydney, New South Wales 2006, Australia [3] Department of Surgical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales 2145, Australia.
⁹ Oncogenomics Laboratory, QIMR Berghofer Medical Research Institute, Herston, Brisbane, Queensland 4006, Australia.
¹⁰ 1] Melanoma Institute Australia, Sydney, New South Wales 2060, Australia [2] Departments of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales 2006, Australia [3] Discipline of Pathology, Sydney Medical School, The University of Sydney, Sydney, New South Wales 2006, Australia.
¹¹ 1] Melanoma Institute Australia, Sydney, New South Wales 2060, Australia [2] Discipline of Medicine, Sydney Medical School, The University of Sydney, Sydney, New South Wales 2006, Australia [3] Precision Cancer Therapy Laboratory, Australian School of Advanced Medicine, Macquarie University, Sydney, New South Wales 2109, Australia [4] Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia.

PMID: 25452114
DOI: 10.1038/ncomms6694

Abstract

One-third of BRAF-mutant metastatic melanoma patients treated with combined BRAF and MEK inhibition progress within 6 months. Treatment options for these patients remain limited. Here we analyse 20 BRAF(V600)-mutant melanoma metastases derived from 10 patients treated with the combination of dabrafenib and trametinib for resistance mechanisms and genetic correlates of response. Resistance mechanisms are identified in 9/11 progressing tumours and MAPK reactivation occurred in 9/10 tumours, commonly via BRAF amplification and mutations activating NRAS and MEK2. Our data confirming that MEK2(C125S), but not the synonymous MEK1(C121S) protein, confers resistance to combination therapy highlight the functional differences between these kinases and the preponderance of MEK2 mutations in combination therapy-resistant melanomas. Exome sequencing did not identify additional progression-specific resistance candidates. Nevertheless, most melanomas carried additional oncogenic mutations at baseline (for example, RAC1 and AKT3) that activate the MAPK and PI3K pathways and are thus predicted to diminish response to MAPK inhibitors.

PubMed Disclaimer

Cited by

Investigating the Retained Inhibitory Effect of Cobimetinib against p.P124L Mutated MEK1: A Combined Liquid Biopsy and in Silico Approach.
Catoni C, Poggiana C, Facchinetti A, Pigozzo J, Piccin L, Chiarion-Sileni V, Rosato A, Minervini G, Scaini MC. Catoni C, et al. Cancers (Basel). 2022 Aug 27;14(17):4153. doi: 10.3390/cancers14174153. Cancers (Basel). 2022. PMID: 36077693 Free PMC article.
Discovery of SHR2415, a Novel Pyrrole-Fused Urea Scaffold ERK1/2 Inhibitor.
Li X, Dong P, Zhang T, Cai G, Chen Y, Dong H, Yang F, Zhang L, Mao Y, Feng J, Bai C, He F, Tao W. Li X, et al. ACS Med Chem Lett. 2022 Apr 1;13(4):701-706. doi: 10.1021/acsmedchemlett.2c00029. eCollection 2022 Apr 14. ACS Med Chem Lett. 2022. PMID: 35450372 Free PMC article.
Drugging the Epigenome: Overcoming Resistance to Targeted and Immunotherapies in Melanoma.
Hanly A, Gibson F, Nocco S, Rogers S, Wu M, Alani RM. Hanly A, et al. JID Innov. 2021 Dec 13;2(2):100090. doi: 10.1016/j.xjidi.2021.100090. eCollection 2022 Mar. JID Innov. 2021. PMID: 35199090 Free PMC article. Review.
Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors.
Lebedev TD, Khabusheva ER, Mareeva SR, Ivanenko KA, Morozov AV, Spirin PV, Rubtsov PM, Snezhkina AV, Kudryavtseva AV, Sorokin MI, Buzdin AA, Prassolov VS. Lebedev TD, et al. J Biol Chem. 2022 Aug;298(8):102226. doi: 10.1016/j.jbc.2022.102226. Epub 2022 Jul 1. J Biol Chem. 2022. PMID: 35787369 Free PMC article.
Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma.
Janostiak R, Malvi P, Wajapeyee N. Janostiak R, et al. iScience. 2019 Jun 28;16:453-467. doi: 10.1016/j.isci.2019.06.001. Epub 2019 Jun 8. iScience. 2019. PMID: 31229894 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Associated data

Actions
- Search in PubMed
- Search in GEO

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
Medical
- MedlinePlus Health Information
Molecular Biology Databases
- NIAID Data Ecosystem - Find datasets on Infectious and Immune-mediated Diseases
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

Affiliations

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

Authors

Affiliations

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

Associated data

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Research Materials

Miscellaneous

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

Associated data

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Research Materials

Miscellaneous